Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms

1 Jan 2020

Abstract excerpt

Androgen deprivation therapy targeting the androgens/androgen receptor (AR) signaling continues to be the mainstay treatment of advanced-stage prostate cancer. The use of second-generation antiandrogens, such as abiraterone acetate and enzalutamide, has improved the survival of prostate cancer patients; however, a majority of these patients progress to castration-resistant prostate cancer (CRPC). The mechanisms...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Lipids, and Metabolism
Share to Estrogen and related hormone effects
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35582225
DOI: 10.20517/cdr.2020.45

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance to second generation antiandrogens in prostate cancer: pathways and mechanismsPMID 35582225Read ↗

Novel hormone therapies for advanced prostate cancer: Understanding and countering drug resistanceSemantic proximity Read ↗

Mechanisms of resistance to androgen deprivation therapy in prostate cancer.Semantic proximity Read ↗

Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical ApplicationsSemantic proximity Read ↗

Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer.Semantic proximity Read ↗

Targeting the androgen receptor and overcoming resistance in prostate cancerSemantic proximity Read ↗

Androgen Receptor Signaling in Prostate Cancer and Therapeutic StrategiesSemantic proximity Read ↗

Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.Semantic proximity Read ↗

A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509Semantic proximity Read ↗

Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate CancerSemantic proximity Read ↗

Overcoming castration resistance in prostate cancer.Semantic proximity Read ↗

New Opportunities for Targeting the Androgen Receptor in Prostate Cancer.Semantic proximity Read ↗

Targeting extra-gonadal androgens in castration-resistant prostate cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.